Current Data and Considerations Novel Testosterone Formulations
|
|
- Preston Pope
- 5 years ago
- Views:
Transcription
1 Current Data and Considerations Novel Testosterone Formulations 1
2 Hypogonadism: Treatment Safety and Prostate Health 2
3 Monitoring for Testosterone Therapy DRE 1,2 PSA Parameter Voiding/IPSS 1,2 Hemoglobin Hematocrit 1,2 Breast examination 1,2 Sleep apnea 1,2 Frequency Baseline, at 3 and 6 months, yearly thereafter Baseline; prostate-related symptom assessment every 6 to 12 months Baseline, at 3 and 6 months, yearly thereafter 1,2 Baseline, at 3 and 6 months, yearly thereafter Baseline and follow-up Baseline and as needed clinically Comment Biopsy if abnormal baseline and if abnormal during treatment Biopsy if PSA >4. ng/ml 1,2 Biopsy if PSA increases 1. ng/ml or greater within any 12-month period 1 Repeat PSA measurement for PSA increase of.7 to.9 ng/ml 2 Detect possible hematocrit >54% Detect gynecomastia Ask about fatigue during the day and disordered sleep DRE=digital rectal examination. IPSS=International Prostatic Symptom Score. PSA=prostate-specific antigen. 1. Bhasin S et al. J Clin Endocrinol Metab. 26;91: Rhoden EL, Morgentaler A. N Engl J Med. 24;35: Because testosterone (T) affects various organs and tissues, men receiving T therapy should be evaluated at baseline and at follow-up visits, generally at 3 and 6 months after the initiation of therapy and yearly thereafter. 1 Baseline assessments should include a digital rectal examination (DRE) and blood tests to measure prostate-specific antigen (PSA) and the hemoglobin or hematocrit. Voiding symptoms can be assessed by obtaining a history or using an instrument such as the International Prostatic Symptom Score. Patients should also be questioned regarding symptoms of sleep apnea. If the PSA is >4. ng/ml or the DRE is abnormal, a prostate biopsy should be performed. 1,2 At follow-up, urinary symptoms and the presence or exacerbation of sleep apnea or gynecomastia should be monitored. Because increased T levels appear to stimulate erythropoiesis, hemoglobin or hematocrit should be monitored during replacement therapy. 1,2 The risk of erythrocytosis appears to vary with the type of T formulation. 1 DRE should be repeated at follow-up visits. If PSA is >4. ng/ml 1,2 or increases by 1. ng/ml in a year, 1 a prostate biopsy should be performed or the patient should be referred to a urologist. For increases in PSA levels of.7 to.9 ng/ml in 1 year, the PSA measurement should be repeated in 3 to 6 months, and a biopsy should be performed if a further increase is detected Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 24;35: Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 26;91:
4 Potential Class Adverse Effects of Testosterone Treatment Adverse Effect Prostate cancer 1-8 Benign prostatic hyperplasia 1-6 Testicular atrophy or infertility 1-6 Sleep apnea 3,5,7 Acne and oily skin 1-6 Gynecomastia 1-6 Fluid retention 1-6 Comment Controversial; no causal relationship established Infrequently worsened in men with mild or moderate LUTS; avoid in men with severe LUTS (weak data) Common, especially in young men; usually reversible when treatment stops Infrequent; controversial Infrequent Infrequent Rarely of clinical significance; of concern only in men with class III or IV heart failure, chronic renal insufficiency, or severe liver disease 1. Delatestryl [package insert]. Lexington, Mass: Indevus Pharmaceuticals, Inc.; Depo-Testosterone [package insert]. Kalamazoo, Mich: Pharmacia Corporation; AndroGel [package insert]. Marietta, Ga: Solvay Pharmaceuticals, Inc.; Androderm [package insert]. Corona, Calif: Watson Pharma, Inc.; Striant [package insert]. Livingston, NJ: Columbia Laboratories, Inc.; Halotestin [package insert]. Kalamazoo, Mich: Pharmacia Corporation; Bhasin S, Cunningham GR, Hayes FJ, et al. J Clin Endocrinol Metab. 26;91: AACE Hypogonadism Task Force. Endocr Pract. 22;8: In the United States, product labels for testosterone replacement formulations contain standard warnings regarding prostatic hypertrophy and prostatic hyperplasia, suppression of spermatogenesis, acne and oily skin, gynecomastia, and fluid retention. 1-6 In addition, the product labeling for the testosterone buccal system includes a warning that treatment of hypogonadal men with testosterone esters may potentiate sleep apnea, especially in patients with risk factors such as obesity or chronic lung disease. However, the Endocrine Society Clinical Practice Guideline for testosterone therapy notes that this condition arises infrequently in young hypogonadal men. 5,7 With regard to prostate cancer, the American Association of Clinical Endocrinologists guidelines for the treatment of hypogonadism in adult males state that, despite anecdotal reports, no causal relationship has been established between testosterone treatment and prostate cancer Delatestryl [package insert]. Lexington, Mass: Indevus Pharmaceuticals, Inc.; Depo-Testosterone [package insert]. Kalamazoo, Mich: Pharmacia Corporation; AndroGel [package insert]. Marietta, Ga: Solvay Pharmaceuticals, Inc.; Androderm [package insert]. Corona, Calif: Watson Pharma, Inc.; Striant [package insert]. Livingston, NJ: Columbia Laboratories, Inc.; Halotestin [package insert]. Kalamazoo, Mich: Pharmacia Corporation; Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 26;91: AACE Hypogonadism Task Force. Medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients 22 update. Endocr Pract. 22;8:
5 Formulation-Specific Adverse Effects Formulation Injectables Pellet implants Testosterone cypionate/enanthate Testosterone undecanoate* Topical Topical gel Testosterone patch system Oral Buccal system Potential infections or expulsion Mood fluctuations or changes in libido; pain at injection site Excessive erythrocytosis Pain at injection site Dermal testosterone transference Skin irritation Adverse Effect Alterations in taste and irritation of gums and oral mucosa *In development in the United States. Data from Bhasin S et al. J Clin Endocrinol Metab. 26;91: Formulation-specific adverse effects can occur with testosterone replacement therapy. Testosterone pellets are implanted in an office-type minor surgical procedure, which carries the risk of infection or expulsion. Intramuscular injections of testosterone cypionate, enanthate, or undecanoate (in development in the United States) may cause pain at the injection site. Testosterone cypionate or enanthate may cause fluctuations in mood or libido and excessive erythrocytosis, particularly in older patients. The testosterone topical gel can potentially be transferred to the patient s partner. Patients should cover the application site with clothing and wash skin and hands with soap before having skin-to-skin contact. Transdermal testosterone patches may cause skin irritation at the application site. The testosterone buccal system may cause alterations in taste and gum irritation. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 26;91:
6 Results From Long-Term Safety Study* of Testosterone Undecanoate IM Serum trough testosterone levels within normal range Individual dosing intervals ranged from 1 to 14 weeks Patients treated for up to 8.5 years Patients reported restoration of sexual function and positive mood changes No report of mood fluctuations Hemoglobin and hematocrit within normal range Prostate size <3 ml PSA concentrations <2. µg/l Bone density improved *N=22 patients aged 3 to 65 years (mean 43.8 ± 8 years), study duration 8.5 years. Zitzmann M et al. Presented at: ENDO 26; Boston, Mass; June 24 to 27, 26. Abstract P Twenty-two hypogonadal patients aged 3 to 65 years (mean age 43.8 years) were treated with the long-acting ester testosterone undecanoate injected in a dosage of 1, mg at intervals of 1 to 14 weeks. Patients reported restored sexual function, improved vigor, and decreased depression. Fluctuations in mood often seen with short-acting testosterone preparations were not reported. Although treatment was associated with elevations in hemoglobin and hematocrit, values remained within normal limits. Prostate size remained less than 3 ml, and prostate-specific antigen (PSA) values were 2. µg/l. Quantitative computed tomography of the lumbar spine showed improvements in bone density. Testosterone undecanoate was well tolerated. The only adverse effect was moderate local irritation at the injection site that did not last more than 3 days. Zitzmann M, Saad F, Nieschlag E. Longterm experience of up to 8.5 years with a long-acting formulation of testosterone undecanoate in substitution therapy of hypogonadal men. Poster presented at ENDO 26, Boston, Mass; June 24-27, 26. 6
7 Prostate Health Assessment DRE PSA Consult with urologist if PSA >4. ng/ml PSA velocity >.4 ng/ml/year (using PSA level after 6 months of therapy) Detection of prostate abnormality on DRE AUA prostate symptom score >19 AUA=American Urological Association. DRE=digital rectal examination. PSA=prostate-specific antigen. Bhasin S et al. J Clin Endocrinol Metab. 26;91: The Endocrine Society Clinical Practice Guideline recommends a digital rectal examination (DRE) of the prostate and measurement of prostate-specific antigen (PSA) before initiating testosterone therapy. A urologic consultation is recommended if the PSA is >4. ng/ml, the PSA velocity is >.4 ng/ml per year (using the PSA level after 6 months of testosterone therapy), a prostatic abnormality is detected on DRE, or the patient has an American Urological Association prostate symptom score of >19. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 26;91:
8 Prostate Cancer Incidence in Testosterone Therapy Studies (Controlled) Age (y) Study Authors Duration (months) Patients Receiving T (n) Mean Range PCa Cases (n) Route of Administration Kenny et al. (21) Patch Wang et al. (2) Not available 19-68* 1 Gel, patch Snyder et al. (1999) >65 1 Patch Dobs et al. (1999) (gel) 44.9 (IM) Gel, IM Sih et al. (1997) IM *3.9%-8.2% aged 65 in the 3 original treatment groups. PCa=prostate cancer. T=testosterone. 1. Kenny AM et al. J Gerontol A Biol Sci Med Sci. 21;56A:M266-M Wang C et al. J Clin Endocrinol Metab. 2;85: Snyder PJ et al. J Clin Endocrinol Metab. 1999;84: Dobs AS et al. J Clin Endocrinol Metab. 1999;84: Sih R et al. J Clin Endocrinol Metab. 1997;82: Studies of hypogonadal men receiving testosterone therapy using transdermal, topical, intramuscular injection, or a combination of these preparations have demonstrated a low frequency of prostate cancer. A compilation of published prospective studies of testosterone replacement revealed only 5 cases of prostate cancer among 388 men (~1.%) followed for 6 to 36 months. 1-5 According to Rhoden and Morgentaler, this prevalence rate is similar to that in the general population Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci. 21;56A:M266- M Wang C, Swerdloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2;85: Snyder PJ, Peachey H, Hannoush P, et al. Effects of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab. 1999;84: Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab. 1999;84: Sih R, Morley JE, Kaiser FE, Perry HM III, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab. 1997;84: Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. New Engl J Med. 24;35:
9 Prostate Cancer Incidence in Testosterone Therapy Studies (Non-Controlled) Study Authors Duration (months) Patients Receiving T (n)* Mean Not available Age (y) Range PCa Cases (n) Route of Administration Wang et al. Not Not Gel (24) 1 available available Schubert et IM TU 3 36 al. (24) IM TE Rhoden et al. (23) 3 Gerstenbluth et al. (22) 4 Snyder et al (2) 5 12 Mean (PIN+) 55 (PIN-) IM, gel IM, gel IM Patch *n=total number of patients remaining at end of study. Median=51. PCa=prostate cancer. PIN+=prostatic intraepithelial neoplasia without frank cancer. PIN =PIN with benign prostate biopsy. 1. Wang C et al. J Clin Endocrinol Metab. 24;89: Shubert M et al. J Clin Endocrinol Metab. 24;89: Rhoden EL, Morgentaler A. J Urol. 23;17: Gerstenbluth RE et al. J Androl. 22;23: Snyder PJ et al. J Clin Endocrinol Metab. 2;85: These non-controlled studies of hypogonadal men receiving testosterone (T) therapy also demonstrate a low incidence of prostate cancer. Among 32 men receiving either a transdermal, topical, or intramuscular T formulation for 12 to 36 months, only 5 cases of prostate cancer were detected (1.7%). 1-5 After their retrospective study of 54 men, Gerstenbluth et al also conducted one of the longest follow-up evaluations of a significant number of hypogonadal men. They performed a subset analysis of 19 men who continued T therapy for at least 36 months (mean, 58.5 months). No patient in this follow-up group was diagnosed with prostate cancer, suggesting that, after 4 to 5 years of sustained T therapy, risk of prostate cancer did not increase Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 24;89: Schubert M, Minnemann T, Hübler D, et al. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab. 24;89: Rhoden EL, Morgentaler A. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol. 23;17: Gerstenbluth RE, Maniam PN, Corty EW, Seftel AD. Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement. J Androl. 22;23: Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab. 2;85:
10 Relationship of PSA Levels to Prevalence of Prostate Cancer Total PSA (ng/ml).5.6 to to to to 4. Probability of Prostate Cancer (%) N=2,95 men aged 62 to 91 years. PSA=prostate-specific antigen. Reprinted with permission from Thompson IM et al. N Engl J Med. 24;35: The prevalence of prostate cancer was determined in 2,95 men (aged 62 to 91 years) in the placebo arm of the Prostate Cancer Prevention Trial who never had a prostate-specific antigen (PSA) level >4. ng/ml or an abnormal annual digital rectal examination result during 7 years in the study. Prostate cancer was diagnosed in 15.2% (449) of the 2,95 men, and 14.9% (67) of these cancers were high grade (Gleason score of 7 or higher). As shown here, the prevalence of prostate cancer increased as the PSA level increased, ranging from 6.6% among men with a PSA.5 ng/ml to 26.9% among men with a PSA of 3.1 to 4. ng/ml. Although PSA levels 4. ng/ml are generally considered normal, these findings show that prostate cancer is not uncommon in men with these levels. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level 4. ng per milliliter. N Engl J Med. 24;35:
11 Effect of Testosterone Therapy on Prostate Tissue in Men With Late-Onset Hypogonadism Study Design BIOPSY 17 screened 48 enrolled* 6-month, randomized, controlled trial (Feb 3 - Nov 4) 44 randomized RE-BIOPSY Testosterone mg IM every 2 weeks 4 completed Placebo 19 *4 excluded (prostate cancer on first biopsy). 1 discontinuation (erythrocytosis). 2 discontinuations (1 GI cancer, 1 moved), 1 excluded (elevated baseline testosterone level). GI=gastrointestinal. Data from Marks LS et al. JAMA. 26;296: prostate cancers 4 prostate cancers To determine the effects of testosterone (T) therapy on prostate tissue, a randomized, double-blind, placebo-controlled trial was conducted in men aged 44 to 78 years with screening T levels <3 ng/dl and related symptoms. Of 17 men screened, 48 men met enrollment criteria, but 4 were found to have prostate cancer. Thus, 44 men were randomized to receive 15 mg of testosterone enanthate or matching placebo intramuscularly every 2 weeks for 6 months. A total of 4 men (21 T therapy, 19 placebo) had prostate biopsies performed at baseline and at 6 months and qualified for the per-protocol analysis. One man assigned to T therapy discontinued early because of erythrocytosis. Two men assigned to placebo discontinued early, 1 because of gastrointestinal cancer and 1 who moved away, and a third man assigned to placebo was excluded from the analysis because of an elevated baseline T level found at the end-of-study batch analysis. Re-biopsy at 6 months detected prostate cancer in 2 of 21 men in the T therapy group and 4 of 19 men in the placebo group. In each group, 1 man had a Gleason grade 7 cancer; each man showed a modest increase in serum prostate-specific antigen during the trial. The other cancers were Gleason grade 6 lesions. Marks LS, Mazer NA, Mostaghel E, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 26;296:
12 Effect of Testosterone Therapy on Prostate Tissue in Men With Late-Onset Hypogonadism Serum Levels Testosterone Dihydrotestosterone 1,5 Serum (ng/dl) 1, 5 Serum (ng/dl) 1 5 Baseline 6 Months Baseline 6 Months Baseline 6 Months Baseline 6 Months Placebo Active =outlier. Reprinted with permission from Marks LS et al. JAMA. November 15, 26;296: Copyright 26 American Medical Association. Serum levels of testosterone (T) and dihydrotestosterone (DHT) were determined in morning blood samples collected at baseline and during study visits at 6 weeks, 3 months, and 6 months. Baseline and 6-month data are compared here. After 6 months of T therapy, serum T levels increased to the mid-normal range (median at baseline, 282 ng/dl; median at 6 months, 64 ng/dl), with no significant change in serum T levels in placebo-treated men. Serum DHT increased from a median of 28 ng/dl at baseline to a median of 47 ng/dl after 6 months of T therapy, but decreased slightly in the placebo group from 28 ng/dl to 26 ng/dl. Overall, average increases in the T therapy group were 138% for T and 65% for DHT. Marks LS, Mazer NA, Mostaghel E, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 26;296:
13 Effect of Testosterone Therapy on Prostate Tissue in Men With Late-Onset Hypogonadism Prostate Tissue Levels Testosterone Dihydrotestosterone 25 4 Tissue (ng/g) Tissue (ng/g) 2 1 Baseline 6 Months Baseline 6 Months Baseline 6 Months Baseline 6 Months Placebo Active =outlier. Intraprostatic concentrations of testosterone and dihydrotestosterone did not differ after therapy despite substantial changes in serum concentrations. Reprinted with permission from Marks LS et al. JAMA. November 15, 26;296: Copyright 26 American Medical Association. Determinations of prostate androgens (testosterone [T] and dihydrotestosterone [DHT]) were performed on quick-frozen biopsy cores (5-1 mg). As shown here, intraprostatic concentrations of T and DHT did not differ after therapy despite increases of 138% and 65%, respectively, in serum concentrations. The median T level was.91 ng/g at baseline and 1.55 ng/g (P=.29) after 6 months of T therapy, and the median DHT level was 6.79 ng/g at baseline and 6.82 ng/g posttreatment (P=.51). Marks LS, Mazer NA, Mostaghel E, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 26;296:
14 Occult Prostate Cancer in Men With Low Testosterone Levels Objective Determine prevalence of prostate cancer in men with low TT or FT levels Design Prostate biopsy in consecutive patients Patients Men (n=345) with low TT or FT levels, with normal DRE examination and PSA levels 4. ng/ml DRE=digital rectal examination. FT=free testosterone. PSA=prostate-specific antigen. TT=total testosterone. Morgentaler A, Rhoden EL. Urology. 26;68: The prevalence of prostate cancer was determined in 345 consecutive men with a prostate-specific antigen (PSA) level of 4. ng/ml who underwent digital rectal examination (DRE) and prostate biopsy before initiating testosterone (T) therapy. All of the men had low serum levels of total T (184 men, 53.3%), defined as <3 ng/dl, or free T (327 men, 94.8%), defined as <1.5 ng/dl. All of the men had a PSA 4. ng/ml, and 7.1% had normal findings on DRE. Morgentaler A, Rhoden EL. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4. ng/ml or less. Urology. 26;68:
15 Prostate Cancer Prevalence in Hypogonadal Men With PSA Levels of 4. ng/dl Men With Prostate Cancer (%) * 26.4* 36.4 to 1. (n=162) 1.1 to 2. (n=97) PSA (ng/ml) 2.1 to 3. (n=53) 3.1 to 4. (n=33) *P<.5 vs men with PSA of to 1. ng/ml. P<.5 vs men with PSA of to 1. and 1.1 to 2. ng/ml. Reprinted with permission from Morgentaler A, Rhoden EL. Urology. 26;68: Biopsy revealed prostate cancer in 52 (15.1%) of the 345 men. As shown here, the relationship between cancer risk and increasing PSA level was linear. Men with a PSA level of 3.1 to 4. ng/ml had the highest rate of prostate cancer 36.4% whereas the rate of prostate cancer was about 11% among men with a PSA level of 2. ng/ml. Even men with a PSA level of 1. had a cancer rate of 5.6%, indicating that no level of PSA was without risk. In addition, the risk of prostate cancer increased with lower testosterone levels. Morgentaler A, Rhoden EL. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4. ng/ml or less. Urology. 26;68:
16 Low Testosterone Levels Associated With High-Grade Prostate Cancer Testosterone (ng/dl) * 1 5 (n=34) 6 (n=33) 7 (n=51) 8 (n=38) Gleason Score *P<.1. Data from Schatzl G et al. Prostate. 21;47: Another study of 156 patients newly diagnosed with prostate cancer found an association between low testosterone (T) levels and high-grade cancer. Fifty-two of the patients (33%) had a serum T level <3 ng/dl. As shown here, the mean T level was significantly lower in men with Gleason scores 8 than in those with Gleason scores 5 (28 ng/dl vs 41 ng/dl, P<.1). Schatzl G, Madersbacher S, Thurridl T, et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate. 21;47:
17 Hypogonadal Men Treated With Testosterone After Radical Prostatectomy Patient No. (Age, years) Year of Prostatectomy Gleason Score/Surgical Margin Pre- Prostatectomy PSA Serum T Before Treatment T Start T Formulation Serum T After Treatment 1 (7) /Neg Patch (5) /Pos 5.2 Not available 1991 Depot Not available 3 (66) 21 7/Neg Gel (64) 22 6/Neg Gel 37 5 (67) /Neg Not available Not available 2 Depot 74 6 (55) 22 6/Neg 4.7 Not available 22 Patch (64) /Neg Not available Patch 545 PSA=prostate-specific antigen. T=testosterone. This table was published in Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol. 24;172: Copyright by American Urological Association 24. A retrospective review of clinical records from 2 private urology practices identified 7 hypogonadal men who were treated with an androgen preparation after curative radical prostatectomy. Before treatment, all 7 men had clinical symptoms of hypogonadism and low levels of serum testosterone. Details of each case are summarized here. After follow-up ranging from 1 to 12 years, no evidence of local recurrence or distant spread of prostate cancer was found in the 7 men who received testosterone. Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol. 24;172:
18 Testosterone Therapy After RRP in Patients With Prostate Cancer Objective Study hypogonadal patients treated with RRP to determine whether testosterone therapy could be efficacious and safe without causing recurrent prostate tumor Method Hypogonadal patients (n=1) previously treated with RRP presented with low TT and symptoms of hypogonadism Baseline data Mean age: 64 years Mean PSA: pre-op =7 ng/ml, post-op <.1 ng/ml Mean T: pre-op =469 ng/dl, post-op =197 ng/dl Gleason score: 6-8 Results Mean T increased significantly from 197 ng/dl to 591 ng/dl (P=.2) No detectable increase in PSA (all were <.1 ng/ml) PSA=prostate-specific antigen. RRP=radical retropubic prostatectomy. T=testosterone. TT=total testosterone. Agarwal PK, Oefelein MG. J Urol. 25;173: A retrospective review of patients with cancer confined to the prostate who were treated for hypogonadism after radical retropubic prostatectomy was undertaken to determine whether testosterone (T) replacement therapy could be effective and safe without causing recurrent prostate tumor. Ten patients who underwent radical retropubic prostatectomy between 1993 and 23 were identified. Postoperatively they had no clinical or prostate-specific antigen (PSA) evidence of disease but presented with complaints of decreased libido, erectile dysfunction, lack of energy, cognitive impairment, hot flashes, or a combination of these symptoms. Baseline serum PSA was measured to exclude recurrent prostate cancer, and baseline serum T levels were determined to confirm hypogonadism. The mean age of the men was 64.3 years. Preoperatively, PSA was 7. ng/ml and T (available in 5 patients) was 469 ng/dl. Gleason scores obtained from prostate adenocarcinoma specimens ranged from 6 to 8. Postoperative values for PSA and T were <.1 ng/ml and 197 ng/dl. Patients received either topical T gel or patch or intramuscular testosterone cypionate and were followed every 2 months. After starting T replacement therapy, mean serum T increased significantly from 197 ng/dl to 591 ng/dl (P=.2). The median duration of T replacement therapy was 19 months. No patient had detectable PSA (>.1 ng/ml). Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol. 25;173:
19 Testosterone Therapy After Treatment of Early Prostate Cancer With Brachytherapy Testosterone Levels and Follow-Up Variable Testosterone (ng/dl) Range Median Before testosterone therapy With testosterone therapy* 3 to to 1, Duration (years) Testosterone therapy Follow-up.5 to to *Testosterone therapy started.5 to 4.5 years after brachytherapy. N=31. CANCER, Vol. 19, No. 3, 27, p Copyright 27 American Cancer Society. This material is reproduced with permission of Wiley-Liss, Inc., a subsidiary of John Wiley & Sons, Inc. Records of 31 men who underwent prostate brachytherapy from 1996 to 24 and received subsequent testosterone (T) therapy for hypogonadism were reviewed to assess the risk of biochemical failure or prostate cancer recurrence. The duration of T therapy after prostate brachytherapy ranged from.5 to 8.5 years (median 4.5 years), with a follow-up ranging from 1.5 to 9. years (median 5. years). T therapy was initiated from.5 to 4.5 years (median, 2. years) after brachytherapy. Median serum testosterone levels were 188 ng/dl before T therapy and rose to 498 ng/dl with T therapy. Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer. 27;19:
20 Recent PSA Levels in Men Receiving Testosterone After Brachytherapy PSA (ng/ml) <.1 <.5 <1. No. of Patients (%) 23 (74.2) 3 (96.7) 31 (1) PSA=prostate-specific antigen. CANCER, Vol. 19, No. 3, 27, p Copyright 27 American Cancer Society. This material is reproduced with permission of Wiley-Liss, Inc., a subsidiary of John Wiley & Sons, Inc. One patient had transient increases in prostate-specific antigen after testosterone therapy, followed by decreases. The most recent prostate-specific antigen levels were <.1 ng/ml in 23 men (74.2%), <.5 ng/ml in 3 men (96.7%), and <1. ng/ml in all 31 men. Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer. 27;19:
21 Summary Eugonadal testosterone levels are a critical component of men s overall health and sexual well-being Clinical benefits of testosterone therapy may include improvements in libido, erectile function, mood, bone mineral density, and body composition No evidence indicates that testosterone therapy increases prostate cancer risk but careful monitoring of prostate health is mandatory Some evidence indicates that men with low testosterone levels may have increased risk of prostate cancer and of high-grade prostate cancer Men who have been treated for prostate cancer must receive individualized treatment and be monitored carefully Follow-up visits are essential to assess efficacy and safety Eugonadal testosterone (T) levels are a critical component of men s overall health and sexual well-being. Clinical benefits of T therapy in hypogonadal men may include improvements in libido, erectile function, mood, bone mineral density, and body composition. Clinical experience to date has shown no evidence to suggest that T therapy increases the risk of prostate cancer. However, careful monitoring of prostate health during T therapy is mandatory. Some evidence suggests that men with low T levels may have an increased risk of prostate cancer and of high-grade prostate cancer. After treatment for prostate cancer, men experiencing symptoms of hypogonadism need to be treated on an individual basis and monitored very carefully. Follow-up visits are essential to monitor efficacy and safety for patients who are currently receiving or who have previously received T therapy. 21
Testosterone Therapy and the Prostate. Frans M.J. Debruyne Professor of Urology The Netherlands
Testosterone Therapy and the Prostate Frans M.J. Debruyne Professor of Urology The Netherlands TRT- Risks Prostate ( Cancer, BPH )? Cardiac? Lipids? Polycythemia Sleep apnea Gynecomastia Edema Testosterone
More information6/14/2010. GnRH=Gonadotropin-Releasing Hormone.
Male Androgen Replacement Mitchell Sorsby, MD June 19, 2010. QUESTION # 1 Which of the following is not a symptom associated with low T levels? a) decreased libido b) erectile dysfunction c) depression
More informationTestosterone Substitution and the Prostate
European Urology Supplements European Urology Supplements 4 (2005) 16 23 Testosterone Substitution and the Prostate E. David Crawford* University of Colorado Health Sciences Center, 1665 N. Ursula Street,
More informationPCa Commentary. Prostate Cancer? Where's the Meat? - A Collection of Studies Supporting the Safety of Its Use. Seattle Prostate Institute CONTENTS
Volume 70 July - August 2011 PCa Commentary SEATTLE PROSTATE INSTITUTE CONTENTS TESTOSTERONE REPLACEMENT in Hypogonadal Men with Treated and Untreated Prostate Cancer? 1 TESTOSTERONE REPLACEMENT in Hypogonadal
More informationTestim 1 Gel: Review of Clinical Data
European Urology Supplements European Urology Supplements 4 (2005) 24 30 Testim 1 Gel: Review of Clinical Data Tom A. McNicholas* Department of Urology, Lister Hospital, Corey s Mill Lane, Stevenage, Hertfordshire
More informationPREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS
ADULT UROLOGY PREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS ABRAHAM MORGENTALER AND ERNANI LUIS RHODEN ABSTRACT Objectives. To determine
More informationPoint-Counterpoint: Late Onset Hypogonadism (LOH)
Point-Counterpoint: Late Onset Hypogonadism (LOH) We are Under-diagnosing and Treating Men with LOH LOH is a Non-existent Disease ~ Robert E. Donohue, MD Late Onset Hypogonadism LOH: underdx. & undertx
More informationHow to treat: TRT modalities and formulations
How to treat: TRT modalities and formulations Paul PIETTE, PharmD Senior Research Fellow Clinique Antoine Depage - Belgium ppiette@besins-healthcare.com Bruges 2014, May 15 th Testosterone-replacement
More informationTRT and localized protate cancer
TRT and localized protate cancer Frans M. J. Debruyne Professor of Urology PRISM BRUGES Increased risk of prostate cancer with TRT? Prostate cancer Testosterone and Prostate Cancer There appears to be
More informationEvaluation and Treatment of Primary Androgen Deficiency Syndrome in Male Patients
Evaluation and Treatment of Primary Androgen Deficiency Syndrome in Male Patients Jeff Unger, MD Director Chino Medical Group Diabetes and Headache Intervention Center Chino, California January 16, 2008
More informationManaging Testosterone Deficiency: A Practical Guide. John Grantmyre MD Professor of Urology Dalhousie University
Managing Testosterone Deficiency: A Practical Guide John Grantmyre MD Professor of Urology Dalhousie University 1 2 Case Study #1 A 59-Year-Old Man with Erectile Dysfunction 3 Case History Robert is a
More informationTestosterone Injection and Implant
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.33 Subject: Testosterone Injection Implant Page: 1 of 10 Last Review Date: November 30, 2018 Testosterone
More informationAndroderm patch, AndroGel packets and pump, Axiron solution, First- Testosterone, First-Testosterone MC, Fortesta gel, Testim gel, Vogelxo
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.31 Subject: Testosterone Topical Page: 1 of 9 Last Review Date: September 23, 2016 Testosterone topical
More informationTestosterone and the Prostate
Testosterone and the Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David and Vicki M. Crawford Endowed Chair in Urologic Oncology University
More informationOutcomes of Prostate Biopsy in Men with Hypogonadism Prior or During Testosterone Replacement Therapy
ORIGINAL ARTICLE Vol. 41 (6): 1167-1171, November. December, 2015 doi: 10.1590/S1677-5538.IBJU.2014.0528 Outcomes of Prostate Biopsy in Men with Hypogonadism Prior or During Testosterone Replacement Therapy
More informationHYPOGONADISM DEFINITION: PRODUCTION OF SEX HORMONES AND GERM CELLS IS INADEQUATE (ENDOCRINE SOCIETY)
HYPOGONADISM DEFINITION: PRODUCTION OF SEX HORMONES AND GERM CELLS IS INADEQUATE (ENDOCRINE SOCIETY) DEFECT OF THE REPRODUCTIVE SYSTEM THAT RESULTS IN LACK OF FUNCTION OF THE GONADS (Wikipedia) REDUCTION
More informationTestosterone Injection / Implant
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Testosterone Injection / Implant Page: 1 of 9 Last Review Date: December 5, 2014 Testosterone
More informationA dro r gen e R e R p e lac a e c m e e m n e t t T her e a r p a y Androgen Replacement Therapy in the Aging O j b ecti t ve v s Male
Androgen Replacement Therapy in the Aging Male Thomas J. Walsh, MD, MS Department of Urology University of California, San Francisco Objectives 1. List 3 effects of androgens on normal male physiology.
More informationTestosterone Injection and Implant
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.33 Subject: Testosterone Injection Implant Page: 1 of 10 Last Review Date: December 8, 2017 Testosterone
More informationGUIDELINES ON. Introduction. G.R. Dohle, S. Arver, C. Bettocchi, S. Kliesch, M. Punab, W. de Ronde
GUIDELINES ON Male Hypogonadism G.R. Dohle, S. Arver,. Bettocchi, S. Kliesch, M. Punab, W. de Ronde Introduction Male hypogonadism is a clinical syndrome caused by androgen deficiency. It may adversely
More informationHypogonadism 4/27/2018. Male Hypogonadism -- Definition. Epidemiology. Objectives HYPOGONADISM. Men with Hypogonadism. 95% untreated.
Male Hypogonadism -- Definition - Low T, Low Testosterone Hypogonadism -...a clinical syndrome that results from failure of the testes to produce physiological concentrations of testosterone due to pathology
More informationDoes TRT Induce Prostate Cancer?
Does TRT Induce Prostate Cancer? Prism VI, Bruges, Belgium 21-22November 2014 Herman Leliefeld, Urologist, Utrecht The Netherlands Does TRT Induce Prostate Cancer? Why is it a controversial topic? Is there
More informationTestosterone Injection and Implant
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.33 Subject: Testosterone Injection Implant Page: 1 of 10 Last Review Date: March 17, 2017 Testosterone
More informationTestosterone Update: Bridging the Treatment Gaps in the Management of Hypogonadism EDITORS LETTER STATEMENT OF NEED OBJECTIVES
Testosterone Update: Bridging the Treatment Gaps in the Management of Hypogonadism Co-Chairpersons Glenn R. Cunningham, MD Professor of Medicine and Molecular & Cellular Biology Baylor College of Medicine
More informationCorporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency
Corporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency File Name: Origination: Last CAP Review: Next CAP Review: Last Review: testosterone_pellet_implantation_for_androgen_deficiency
More informationTestosterone (cypionate, enanthate, and propionate) powder, Fluoxymesterone powder, Methyltestosterone powder
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.37 Subject: Testosterone Powder Page: 1 of 12 Last Review Date: November 30, 2018 Testosterone powder
More informationTestosterone Oral Buccal Nasal. Android, Androxy, Methitest, Natesto, Striant, Testred. Description
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.32 Subject: Testosterone Oral Buccal Nasal Page: 1 of 10 Last Review Date: March 17, 2017 Testosterone Oral Buccal Nasal Description
More informationTestosterone (cypionate, enanthate, and propionate) powder, Fluoxymesterone powder, Methyltestosterone powder
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.08.37 Subject: Testosterone Powder Page: 1 of 11 Last Review Date: September 18, 2015 Testosterone powder
More informationTestosterone Oral Buccal Nasal. Android, Androxy, Methitest, Natesto, Striant, Testred. Description
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.32 Subject: Testosterone Oral Buccal Nasal Page: 1 of 10 Last Review Date: June 24, 2016 Testosterone Oral Buccal Nasal Description
More informationTestosterone Oral Buccal Nasal. Android, Androxy, Methitest, Natesto, Striant, Testred. Description
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.32 Subject: Testosterone Oral Buccal Nasal Page: 1 of 10 Last Review Date: November 30, 2018 Testosterone Oral Buccal Nasal
More informationGUIDELINES ON MALE HYPOGONADISM
GUIDELINES ON MALE HYPOGONADISM (Text update March 2015) G.R. Dohle (Chair), S. Arver, C. Bettocchi, T.H. Jones, S. Kliesch, M. Punab Introduction Male hypogonadism is a clinical syndrome caused by androgen
More informationBIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
More informationTESTOSTERONE REPLACEMENT THERAPY
TESTOSTERONE REPLACEMENT THERAPY Testosterone is the hormone responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These include
More informationRisks of Testosterone-Replacement Therapy and Recommendations for Monitoring
The new england journal of medicine review article From the Division of Urology, Beth Israel Deaconess Medical Center, and Harvard Medical School both in Boston. Address reprint requests to Dr. Morgentaler
More informationAndrogens. Medication Strengths Quantity Limit Comments Androderm (testosterone patch) 1% pump 2 pump bottles per Non-Preferred
Market DC Androgens Override(s) Prior Authorization Quantity Limit Approval Duration Varies upon diagnosis Medication Strengths Quantity Limit Comments Androderm (testosterone patch) AndroGel (testosterone
More informationTobias S. Kohler, MD, MPH, FACS Southern Illinois University School of Medicine AUA SMSNA Program May 7, 2016
Tobias S. Kohler, MD, MPH, FACS Southern Illinois University School of Medicine AUA SMSNA Program May 7, 2016 Abbvie Researcher/Consultant/Grant Funding Boston Scientific Researcher/Consultant/Grant Funding
More informationClinical Policy: Testosterone Pellet (Testopel) Reference Number: CP.CPA.## [Pre-P&T approval] Effective Date:
Clinical Policy: (Testopel) Reference Number: CP.CPA.## [Pre-P&T approval] Effective Date: 07.25.17 Last Review Date: 11.17 Line of Business: Commercial Coding Implications Revision Log See Important Reminder
More informationEAU GUIDELINES ON MALE HYPOGONADISM
EAU GUIDELINES ON MALE HYPOGONADISM (Text update March 2015) G.R. Dohle (Chair), S. Arver, C. Bettocchi, T.H. Jones, S. Kliesch, M. Punab Introduction Male hypogonadism is a clinical syndrome caused by
More informationPeter J. Burrows MD FACS
Testosterone Supplementation, Prostate Cancer Screening and Vitamins Peter J. Burrows MD FACS Clinical Assistant Professor of Urology University of Arizona, College of Medicine Adjunct Assistant Professor
More informationCan men on AS be treated with testosterone?
Can men on AS be treated with testosterone? Professor Bertrand Tombal, MD, PhD Cliniques universitaires Saint-Luc Université catholique de Louvain Brussels, Belgium Conflicts of interest PI or member steering
More informationRecommendations on the diagnosis, treatment and monitoring of Testosterone deficiency (TD) in adult men
Recommendations on the diagnosis, treatment and monitoring of Testosterone deficiency (TD) in adult men Bruno Lunenfeld, George Mskhalaya, Svetlana Kalinchenko, Yulia Tishova, Michael Zitzmann, Stefan
More informationHypogonadism in Men. CME Away India & Sri Lanka March 23 - April 7, 2018
Hypogonadism in Men CME Away India & Sri Lanka March 23 - April 7, 2018 Richard A. Bebb MD, ABIM, FRCPC Consultant Endocrinologist Medical Subspecialty Institute Cleveland Clinic Abu Dhabi Copyright 2017
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
TESTOSTERONE REPLACEMENT THERAPY: ANDRODERM transdermal patch ANDROGEL pump transdermal gel and transdermal gel AXIRON transdermal solution FORTESTA transdermal gel NATESTO nasal gel STRIANT buccal mucoadhesive
More informationComparison of the Effects of Testosterone Gels, Injections, and Pellets on Serum Hormones, Erythrocytosis, Lipids, and Prostate-Specific Antigen
ORIGINAL RESEARCH PHARMACOTHERAPY Comparison of the Effects of Testosterone Gels, Injections, and Pellets on Serum Hormones, Erythrocytosis, Lipids, and Prostate-Specific Antigen Alexander W. Pastuszak,
More informationHIGHLIGHTS. From Testosterone Update Disease State Theater. American Urological Association and Endocrine Society Annual Meetings
HIGHLIGHTS From Testosterone Update Disease State Theater Presentations held at the 2008 American Urological Association and Endocrine Society Annual Meetings Jointly sponsored by the Annenberg Center
More informationOver the past decade, androgen replacement
J. Andrew Hoover, MD; Jeffrey T. Kirchner, DO, FAAFP Department of Family and Community Medicine, Lancaster General Hospital, Pa jhoover4@lghealth.org The authors reported no potential conflict of interest
More informationTestosterone Replacement Therapy for Hypogonadism: Learning Objectives. What Is the Evidence? Is It Safe? Case Study. Case Study contd.
4 4:4pm Testosterone Therapy: Examining the Evidence SPEAKER Culley Carson, MD Presenter Disclosure Information The following relationships exist related to this presentation: Culley Carson, MD: Consultant
More informationRecognizing and Managing Testosterone Deficiency
Recognizing and Managing Testosterone Deficiency J. Bruce Redmon, M.D. Professor Division of Endocrinology Departments of Medicine and Urologic Surgery Disclosure Information I have no financial relationships
More informationLate onset Hypogonadism. Dr KhooSay Chuan Department of Urology Penang General Hospital
Late onset Hypogonadism Dr KhooSay Chuan Department of Urology Penang General Hospital Late onset hypogonadism(loh) Definition LOH age associated testoteronedeficiency syndrome (TDS) Male menopause, andropause,
More informationWhat Is the Low T Syndrome? Is Testosterone Supplementation Safe?
What Is the Low T Syndrome? Is Testosterone Supplementation Safe? UCSF Osher Mini Medical School March 7, 2018 Dolores Shoback, MD Staff Physician SF-VAMC Professor of Medicine, UCSF No disclosures or
More informationComparison of Testosterone Replacement Therapy Medications for Treatment of Hypogonadism
Brigham Young University BYU ScholarsArchive All Faculty Publications 2017-01-27 Comparison of Testosterone Replacement Therapy Medications for Treatment of Hypogonadism Karlen Beth Luthy Brigham Young
More information10 Novel Testosterone Formulations and Dosing: Potential Impact on Treatment and Outcomes Ajay Nehra, MD
VOLUME 1 NUMBER 1 MAY 30, 2008 1 Letter From the Co-Chairs Glenn R. Cunningham, MD, and Ridwan Shabsigh, MD 2 CME Accreditation Information 4 Introduction 4 Epidemiology of Hypogonadism Glenn R. Cunningham,
More informationTestosterone Therapy in Men with Hypogonadism
Testosterone Therapy in Men with Hypogonadism (Endocrine Society 2018 Guideline) Ngwe Yin, MD Assistant Clinical Professor of Medicine, UCSF Fresno Medical Education Program Disclosures None Objective
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Testosterone Therapy Table of Contents Coverage Policy... 1 General Background... 6 Coding/Billing Information... 7 References... 7 Effective Date... 1/1/2018
More informationTestosterone Replacement in Adults. John A. Seibel, MD, FACP, MACE
Testosterone Replacement in Adults John A. Seibel, MD, FACP, MACE Disclosures None! *Privately Authenticated Definition of Male Hypogonadism inadequate gonadal function, as manifested by deficiencies in
More informationGA KS KY LA MD NJ NV NY TN TX WA Applicable X X N/A N/A X N/A X X X X X X N/A N/A NA *FHK- Florida Healthy Kids. Androgens
Androgens Override(s) Prior Authorization Quantity Limit Approval Duration Varies upon diagnosis Medication Strengths Quantity Limit Comments Generic Androgel 1% (2.5 g) packet 2 packets per day (testosterone
More informationMale Hypogonadism. Types and causes of hypogonadism. What is male hypogonadism? Symptoms. Testosterone production. Patient Information.
Patient Information English 31 Male Hypogonadism The underlined terms are listed in the glossary. What is male hypogonadism? Male hypogonadism means the testicles do not produce enough of the male sex
More informationEAU GUIDELINES ON MALE HYPOGONADISM
EAU GUIDELINES ON MALE HYPOGONADISM (Limited text update March 2017) G.R. Dohle (Chair), S. Arver, C. Bettocchi, T.H. Jones, S. Kliesch Introduction Male hypogonadism is a clinical syndrome caused by androgen
More informationAbstract and Introduction. Topical/transdermal Therapies
www.medscape.com Testosterone Replacement Therapy for Male Hypogonadism: Part III. Pharmacologic and Clinical Profiles, Monitoring, Safety Issues, and Potential Future Agents A Seftel Int J Impot Res.
More informationTestosterone Treatment: Myths Vs Reality. Fadi Al-Khayer, M.D, F.A.C.E
Testosterone Treatment: Myths Vs Reality Fadi Al-Khayer, M.D, F.A.C.E The Biological Functions of Testosterone in Men Testosterone is essential to the musculoskeletal and metabolic systems throughout a
More informationBest Practices to Improve Patient Outcomes
Best Practices Pearls Practical Primary Care Strategies for Diagnosing and Managing Hypogonadism in Men Utilize lab testing in appropriate patients who have complaints consistent with the often subtle
More informationHormone Replacement Therapy
Hormone Replacement Therapy What Role Should It Play With Our Patients? Noel R. Williams MD, FACOG TESTOSTERONE FOR MEN: SALVATION OR SNAKE OIL? Definition Male hypogonadism means the testicles don't produce
More informationTestosterone Therapy in Men An update
Testosterone Therapy in Men An update SANDEEP DHINDSA Associate Professor of Medicine Director, Division of Endocrinology and Metabolism, Saint Louis University, St. Louis, MO Presenter Disclosure None
More informationMALE HYPOGONADISM: CHOOSING THE APPROPRIATE THERAPY. Michael S. Irwig, M.D. Director, Center for Andrology Division of Endocrinology & Metabolism
MALE HYPOGONADISM: CHOOSING THE APPROPRIATE THERAPY Michael S. Irwig, M.D. Director, Center for Andrology Division of Endocrinology & Metabolism Disclosures Aromatase inhibitors & clomiphene citrate are
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
TESTOSTERONE REPLACEMENT THERAPY: ANDRODERM transdermal patch ANDROGEL pump transdermal gel and transdermal gel ANDROID (methyltestosterone) oral capsule ANDROXY (fluoxymesterone) oral tablet AXIRON transdermal
More informationProf Dato Dr TAN Hui Meng University of Malaya, Kuala Lumpur University of Pennsylvania, USA
Prof Dato Dr TAN Hui Meng University of Malaya, Kuala Lumpur University of Pennsylvania, USA Prevailing context Increase number of men who are potential candidates for Testosterone Replacement Therapy
More informationTestosterone therapy in erectile dysfunction
The Aging Male 2004;7:312 318 Testosterone therapy in erectile dysfunction R. Department of Urology, Columbia University, New York, USA Key words: TESTOSTERONE, TESTOGEL 1, ERECTILE DYSFUNCTION, HYPOGONADISM,
More informationTestosterone: Current Opinion and Controversy
Testosterone: Current Opinion and Controversy Ravi Kacker, MD Metrowest Urology (508) 655 4422 Medical Office Building at Leonard Morse Hospital Disclosures MHB Labs President and CEO of Drug Development
More informationTESTOSTERONE REPLACEMENT THERAPY. WHAT IS THE REAL RISK? WHAT TO DO IN PROSTATE CANCER?
TESTOSTERONE REPLACEMENT THERAPY. WHAT IS THE REAL RISK? WHAT TO DO IN PROSTATE CANCER? TESTOSTERONE REPLACEMENT THERAPY (TRT) Nuno Tomada, MD, PhD Department of Urology of Hospital S. João Faculty of
More informationTestosterone Replacement Therapy and Prostate Cancer Incidence
pissn: 2287-4208 / eissn: 2287-4690 World J Mens Health 2015 December 33(3): 125-129 http://dx.doi.org/10.5534/wjmh.2015.33.3.125 Review Article Testosterone Replacement Therapy and Prostate Cancer Incidence
More informationDepartment of Urology, Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH, USA
(2007) 19, 2 24 & 2007 Nature Publishing Group All rights reserved 0955-9930/07 $30.00 www.nature.com/ijir REVIEW for male hypogonadism: Part III. Pharmacologic and clinical profiles, monitoring, safety
More informationTransdermal testosterone gel: pharmacokinetics, efficacy of dosing and application site in hypogonadal men
Original Article TRANSDERMAL TESTOSTERONE GEL A.W. MEIKLE et al. Testosterone gels are being increasingly used throughout the world. There is still some controversy associated with their use, but many
More informationAn Idea Whose Time Has Come-Male Health Programs: An Opportunity For Clinical Expansion and Better Health
An Idea Whose Time Has Come-Male Health Programs: An Opportunity For Clinical Expansion and Better Health KEVIN R. LOUGHLIN MD,MBA Harvard Medical School Boston, MA THE WEAKER SEX-MALES LIFE EXPECTANCY
More informationGP guide to testosterone replacement therapy in men
GP guide to testosterone replacement therapy in men SPL Mike Kirby FRCP Professor Mike Kirby describes how the diagnosis and treatment of test - osterone deficiency in primary care can lead to improved
More informationWhat Is Prostate Cancer? Prostate cancer is the development of cancer cells in the prostate gland (a gland that produces fluid for semen).
What Is Prostate Cancer? Prostate cancer is the development of cancer cells in the prostate gland (a gland that produces fluid for semen). It is a very common cancer in men; some cancers grow very slowly,
More informationTake-Home Messages: Androgens
Take-Home Messages: Androgens Anthony J. Bella MD, FRCSC Greta and John Hansen Chair in Men s Health Research Division of Urology, Department of Surgery University of Ottawa SUMMARY SLAMS Symposium Clinical
More informationDisclosures. Learning Objectives. Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease. None
Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease Micol S. Rothman, MD Associate Professor of Medicine Endocrinology, Diabetes and Metabolism Clinical Director Metabolic Bone
More informationX/99/$03.00/0 Vol. 84, No. 10 The Journal of Clinical Endocrinology & Metabolism Copyright 1999 by The Endocrine Society
0021-972X/99/$03.00/0 Vol. 84, No. 10 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 1999 by The Endocrine Society Pharmacokinetics, Efficacy, and Safety of a Permeation-
More informationIndex. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Acquired hypogonadism, prevalence of, 165 167 primary, 165 secondary, 167 Adipose tissue, as an organ, 240 241 Adrenal hyperplasia, congenital,
More informationMale Menopause: Disease or Pseudoscience? March 4, 2015 story: FDA to require warning on labels of testosterone products.
Male Menopause: Disease or Pseudoscience? March 4, 2015 story: FDA to require warning on labels of testosterone products. 3-30-2015; web William E. Winter, MD University of Florida Departments of Pathology
More informationImplantable Hormone Pellets
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationComparison of long-acting testosterone undecanoate formulation versus testosterone enanthate on sexual function and mood in hypogonadal men
European Journal of Endocrinology (2009) 160 815 819 ISSN 0804-4643 CLINICAL STUDY Comparison of long-acting testosterone undecanoate formulation versus testosterone enanthate on sexual function and mood
More informationISSM QUICK REFERENCE GUIDE ON TESTOSTERONE DEFICIENCY FOR MEN
International Society for Sexual Medicine - www.issm.info ISSM QUICK REFERENCE GUIDE ON TESTOSTERONE DEFICIENCY FOR MEN Version: September 2015 What is testosterone deficiency? Testosterone deficiency
More informationThe Royal Marsden. Prostate case study. Presented by Mr Alan Thompson Consultant Urological Surgeon
Prostate case study Presented by Mr Alan Thompson Consultant Urological Surgeon 2 Part one Initial presentation A 62 year old male solicitor attends your GP surgery. He has rarely seen you over the last
More informationControversies in Prostate Cancer Screening
Controversies in Prostate Cancer Screening William J Catalona, MD Northwestern University Chicago Disclosure: Beckman Coulter, a manufacturer of PSA assays, provides research support PSA Screening Recommendations
More informationProstate-Specific Antigen (PSA) Test
Prostate-Specific Antigen (PSA) Test What is the PSA test? Prostate-specific antigen, or PSA, is a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA test measures the
More informationConsent for Testosterone Therapy-Men Revised 4/10/18
Consent for Testosterone Therapy in Men You have been diagnosed with or have an increased risk of having a hormone deficiency and your provider has recommended treatment with bio-identical hormone replacement
More informationTestosterone supplementation in the aging male: Which questions have been answered?
The Aging Male, March 2005; 8(1): 31 38 Testosterone supplementation in the aging male: Which questions have been answered? WALTER KRAUSE 1, ULRICH MUELLER 2, & ALLAN MAZUR 3 1 Department of Andrology,
More informationUpdate on diagnosis and complications of adult and elderly male hypogonadism
Hypoandrogenism in the elderly: to treat or not to treat? 12 th Italian AME Meeting; 6 th joint Meeting with AAC Bari november 10th Update on diagnosis and complications of adult and elderly male hypogonadism
More informationDiagnosis and management of testosterone deficiency syndrome in adult men: clinical practice guideline (CMAJ)
Diagnosis and management of testosterone deficiency syndrome in adult men: clinical practice guideline (CMAJ) Alvaro Morales CM MD, Richard A. Bebb MD, Priya Manjoo MD MSc, Peter Assimakopoulos MD, John
More informationMen Getting Older Will Testosterone Keep Him Young?
Men Getting Older Will Testosterone Keep Him Young? Alvin M. Matsumoto, M.D. Associate Director, GRECC V.A. Puget Sound Health Care System Professor, Department of Medicine Division of Gerontology and
More informationANDROGEN DEFICIENCY Update on Evaluation and Management
ANDROGEN DEFICIENCY Update on Evaluation and Management Kristen Gill Hairston, MD, MPH Associate Professor of Internal Medicine Section of Endocrinology and Metabolism Wake Forest University School of
More informationX/00/$03.00/0 Vol. 85, No. 8 The Journal of Clinical Endocrinology & Metabolism. Printed in U.S.A. Copyright 2000 by The Endocrine Society
0021-972X/00/$03.00/0 Vol. 85, No. 8 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 2000 by The Endocrine Society Transdermal Testosterone Gel Improves Sexual Function,
More informationDidactic Series. Hypogonadism and HIV. Daniel Lee, MD UCSD Medical Center, Owen Clinic July 28, 2016
Didactic Series Hypogonadism and HIV Daniel Lee, MD UCSD Medical Center, Owen Clinic July 28, 2016 This project is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department
More informationEndocrine Update Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh
Endocrine Update 2016 Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh Disclosure of Financial Relationships Mary Korytkowski MD Honoraria British Medical Journal Diabetes Research
More informationAdult-onset hypogonadism: evaluation and role of testosterone replacement therapy
Review Article Adult-onset hypogonadism: evaluation and role of testosterone replacement therapy Andrew J. Davidiuk, Gregory A. Broderick Department of Urology, Mayo Clinic, Jacksonville, Florida, USA
More informationHypogonadism and Testosterone Replacement Therapy: Pharmacist
Hypogonadism and Testosterone Replacement Therapy: Practical Insights for the Pharmacist Roger G. Hefflinger, PharmD Associate Professor of Pharmacy Practice and Administrative Services Idaho State University,
More informationNewer Aspects of Prostate Cancer Underwriting
Newer Aspects of Prostate Cancer Underwriting Presented By: Jack Swanson, M.D. Keith Hoffman, NFP Moments Made Possible Objectives To review and discuss Conflicting messages about PSA testing Cautions
More information